Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
Early Phase 1
Not yet recruiting
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Genetic: CRG003 injection
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06178432
- Locations
- 🇨🇳
Huashan Hospital of Fudan University, Shanghai, China
Amphotericin B for Non-HIV Cryptococcal Meningitis Patients
Phase 4
- Conditions
- Cryptococcal MeningitisAntifungal Agents
- Interventions
- Drug: Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.Drug: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06178627
- Locations
- 🇨🇳
The Fourth People's Hospital of Nanning, Nanning, China
🇨🇳Huashan Hospital, Shanghai, Shanghai, China
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
Not Applicable
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: [68Ga]Ga-NOTA-RW102 PET Imaging
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06165874
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
The Role of B7-H4 in Tumor Vaccine
Recruiting
- Conditions
- Glioma
- Interventions
- Biological: tumor vaccine
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT06156150
- Locations
- 🇨🇳
Di Chen, Shanghai, Shanghai, China
Subclinical TB With Innovative Modified Short-course Regimens
Phase 4
Active, not recruiting
- Conditions
- Tuberculosis
- Interventions
- Drug: Standard regimenDrug: Short-course regimen
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 556
- Registration Number
- NCT06153069
- Locations
- 🇨🇳
Huashan Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China
[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain
Not Applicable
Recruiting
- Conditions
- Positron Emission TomographyCerebral Gliosis
- Interventions
- Radiation: [18F]BF3-BPA Injection for PET Imaging
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06148207
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
Not Applicable
Recruiting
- Conditions
- Kidney CancerLymphomasPositron Emission Tomography
- Interventions
- Radiation: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06148220
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Radiation: [68Ga]Ga-NOTA-RG2 PET Imaging
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06148155
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
Not Applicable
Recruiting
- Conditions
- Alzheimer DiseasePositron Emission TomographyNeurodegenerative Diseases
- Interventions
- Radiation: [18F]CSF-23
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06148233
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen
Active, not recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06115824
- Locations
- 🇨🇳
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath